摘要
目的探讨ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术(PCI)后应用替格瑞洛与氯吡格雷的临床疗效。方法选择该院100例2017年1月-2018年5月ST段抬高型心肌梗死经皮冠状动脉介入治疗患者。随机分组,对照组采取氯吡格雷治疗,观察组则采取替格瑞洛治疗。比较两组ST段抬高型心肌梗死经皮冠状动脉介入治疗疗效;并发症发生率;治疗前后患者心功能指标LVESD以及LVEDD;心源性猝死、再发心肌梗死等不良事件发生率。结果观察组有更高的疗效100.00%高于对照组72.00%,差异有统计学意义(χ^2=8.101,P<0.05)。治疗后观察组心功能指标LVESD以及LVEDD变化幅度更大,差异有统计学意义(P<0.05)。观察组并发症发生率和对照组比较有优势,差异有统计学意义(χ^2=7.924,P<0.05),观察组并发症发生率是4.00%,有1例出血和1例呼吸困难。对照组并发症发生率是24.00%,有8例出血和4例呼吸困难。观察组心源性猝死、再发心肌梗死等不良事件发生率低于对照组,差异有统计学意义(χ^2=6.913,P<0.05),其中,对照组有3例急性心力衰竭,3例心源性猝死以及3例再发心肌梗死,2例心律失常。观察组有1例心律失常。结论替格瑞洛治疗ST段抬高型心肌梗死经皮冠状动脉介入治疗效果好。
Objective To investigate the clinical efficacy of ticagrelor and clopidogrel after percutaneous coronary intervention(PCI) in patients with ST-segment elevation myocardial infarction. Methods A total of 100 patients with STsegment elevation myocardial infarction percutaneous coronary intervention were enrolled in the hospital from January2017 to May 2018. Randomized, the control group was treated with clopidogrel, and the observation group was treated with ticagrelor. The curative effect of percutaneous coronary intervention was compared between the two groups with ST-segment elevation myocardial infarction;the incidence of complications;the cardiac function indicators of patients with LVESD and LVEDD before and after treatment;the incidence of adverse events such as sudden cardiac death and recurrent myocardial infarction. Results The observation group had a higher curative effect of 100.00% higher than the control group 72.00%,the difference was statistically significant(χ^2=8.101, P<0.05). After treatment, the cardiac function indexes of LVESD and LVEDD were more significant(P <0.05). The incidence of complications in the observation group was superior to that of the control group,the difference was statistically significant(χ^2=7.924, P <0.05). The incidence of complications in the observation group was 4.00%, 1 case of bleeding and 1 case of dyspnea. The incidence of complications in the control group was 24.00%, with 8 cases of bleeding and 4 cases of dyspnea. The incidence of adverse events such as sudden cardiac death and recurrent myocardial infarction in the observation group was lower than that of the control group,the difference was statistically significant(χ^2=6.913, P<0.05). Among them, 3 cases of acute heart failure, 3 cases of sudden cardiac death and 3 cases of the control group with myocardial infarction, 2 cases of arrhythmia. There was 1 cases arrhythmia in the observation group. Conclusion The effect of ticagrelor in the treatment of ST-segment elevation myocardial infarction with percuta
作者
翁玉龙
WENG Yu-long(Jiangyin People's Hospital,Jiangyin,Jiangsu Province,214400 China)
出处
《系统医学》
2019年第19期43-45,共3页
Systems Medicine
基金
无锡市卫健委2016年科研基金项目（KY2016-063）：基于医联体的移动互联网技术优化急性心肌梗死的急救流程及院外随访体系（Z201609）
关键词
ST段抬高型心肌梗死患者
经皮冠状动脉介入治疗术
替格瑞洛
氯吡格雷
临床疗效
Patients with ST-segment elevation myocardial infarction
Percutaneous coronary intervention
Ticagrelor
Clopidogrel
Clinical efficacy
